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Abstract
Background: Flavonoids, a large group of polyphenolic metabolites derived from plants have received a great deal
of attention over the last several decades for their properties in inflammation and allergy. Quercetin, the most
abundant of plant flavonoids, exerts a modulatory action at nanomolar concentrations on human basophils. As this
mechanism needs to be elucidated, in this study we focused the possible signal transduction pathways which may
be affected by this compound. Methods: K2-EDTA derived leukocyte buffy coats enriched in basophil granulocytes
were treated with different concentrations of quercetin and triggered with anti-IgE, fMLP, the calcium ionophore
A23187 and the phorbol ester PMA in different experimental conditions. Basophils were captured in a flow
cytometry analysis as CD123bright/HLADRnon expressing cells and fluorescence values of the activation markers
CD63-FITC or CD203c-PE were used to produce dose response curves. The same population was assayed for
histamine release.
Results: Quercetin inhibited the expression of CD63 and CD203c and the histamine release in basophils activated
with anti-IgE or with the ionophore: the IC50 in the anti-IgE model was higher than in the ionophore model and
the effects were more pronounced for CD63 than for CD203c. Nanomolar concentrations of quercetin were able to
prime both markers expression and histamine release in the fMLP activation model while no effect of quercetin
was observed when basophils were activated with PMA. The specific phosphoinositide-3 kinase (PI3K) inhibitor
wortmannin exhibited the same behavior of quercetin in anti-IgE and fMLP activation, thus suggesting a role for
PI3K involvement in the priming mechanism.
Conclusions: These results rule out a possible role of protein kinase C in the complex response of basophil to
quercetin, while indirectly suggest PI3K as the major intracellular target of this compound also in human basophils.
Background
Flavonoids include a large group of low molecular
weight polyphenolic secondary plant metabolites which
can be found in fruits and vegetables, and plant derived
b e v e r a g e ss u c ha st e a ,w i n ea n dc o f f e e[ 1 - 3 ] .M o r e
recently, these natural compounds have been recognized
to exert antioxidant [4], anti-bacterial and anti-viral
activity, in addition to anti-allergic effects [5-7], and
exert anti-inflammatory [8], anti-angiogenic, analgesic,
cardiovascular-protective [9], anti-hypertensive [10],
hepatoprotective [11], cytostatic, cancer preventive [12],
apoptotic [13], estrogenic and even anti-estrogenic prop-
erties [14]. Quercetin (2-(3,4- dihydroxyphenyl)- 3,5,7-
trihydroxy- 4H- chromen- 4-one) is the most abundant
of the flavonoids and is commonly used as a food sup-
plement [15], but evidence-based data regarding its clin-
ical efficacy are quite scanty [16]. As well as many other
flavonols, quercetin exerts many effects on inflammation
and allergic responses. In this context quercetin is
known mainly as a strong inhibitor of many effector
functions of leukocytes and mast cells at the micromolar
concentration range: the flavonoid is able to inhibit his-
tamine release from human basophils activated with dif-
ferent agonists [17-19], to decrease the expression of the
basophil activation markers tetraspan CD63 and ecto-
enzyme CD203c [20], to block mast cell degranulation
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production of pro-inflammatory cytokines in HMC-1
mast cell line [22]. This evidence has led to the sugges-
tion that quercetin might be a good candidate for
immuno-modulation and anti-allergic therapy [23]. More-
over, recent evidence from our laboratory has reported
that sub-micromolar concentrations of quercetin, while
inhibiting basophil activation marker expression in cells
stimulated through an IgE-dependent pathway, are able to
prime those markers in a classical non IgE-dependent acti-
vation pattern, such as using a formylated peptide (fMLP)
as soluble agonist [20]. The bimodal pattern showed by
quercetin in basophils activated with fMLP, having the
typical features of a classical hormetic mechanism [24,25],
prompted further investigation.
Aiming at understanding the bimodal mechanism by
which quercetin acts on human basophils, in this study
we investigated some basic signaling events in basophil
activation, such as calcium, protein kinase C (PKC) and
PI3K. From a molecular point of view, quercetin has a
significant bulk of intracellular targets, mainly serine/
threonine and tyrosine kinases, which is very difficult to
disentangle [26]. In basophil biology a first step to be
forwarded could be investigating the differential pattern
between anaphylactic degranulation and piecemeal
degranulation, known to be related to IgE-mediated and
to non-IgE mediated activation pathways, respectively
and to the differential expression of surface molecules
associated to cell activation [27]. This issue can be
focused by the use of inhibitors and regulatory mole-
cules able to dissect these mechanisms. We used a poly-
chromatic flow cytometry approach [28] to investigate
the effect of the flavonoid quercetin on the expression
of membrane markers triggered by several different ago-
nists in normal subjects (healthy screened blood
donors). In parallel, we also evaluated whether the
effects of quercetin on basophil membrane markers
were reproduced using a classical assay of histamine
release. The huge collection of quercetin effects on
countless cellular kinases, transcription factors and regu-
latory proteins, claims for further investigation about the
molecular nature of its pharmacological action. This
study, in addition to representing a contribute to the
comprehension of basophil biology, gives new clues
about the modulatory role of this natural compound in
cells of inflammation and allergy.
Methods
Materials
N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP),
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), quercetin dihydrate (minimum 98% HPLC),
phorbol-12-myristate-13-acetate (PMA), the ionophore
A23187, the PI3K inhibitor wortmannin, Na3-
ethylendiaminetetraacetic acid (EDTA), sodium heparin,
trypan blue and distilled water (HPLC grade, Chroma-
solv® Plus) were all purchased from Sigma (Sigma-
Aldrich GmbH, Germany). Goat anti-human IgE was
purchased from Invitrogen-Caltag Laboratories, (UK).
Histamine enzyme-linked immunosorbent assay (ELISA)
releasing test was purchased from Labor Diagnostika
Nord GmbH & Co., Germany. Mouse anti-human
monoclonal antibodies for flow cytometry evaluation
CD123-PECy5 (isotype IgG1, clone 6H6), CD45-
APCCy7 (isotype IgG1 clone HI30), CD203c-PE (isotype
IgG1 clone NP4D6), CD63-FITC (isotype IgG1 clone
MEM-259) were purchased from Biolegend, San Diego
CA, USA. HLA-DR-PECy7 (isotype IgG2a clone L243)
was purchased from Becton Dickinson, Pharmigen CA,
USA. Pure quercetin was dissolved in DMSO at a stock
solution of 1 mg/ml and stored at +4°C for a maximum
of 6 days; wortmannin was dissolved in DMSO at the
stock concentration of 2 × 10
-3 M, stored at -20°C and
thawed before use. Working solutions were made into
HEPES modified buffer (20 mM HEPES, 127 mM NaCl,
5 mM KCl, 5 UI/ml sodium-heparin, pH 7.4) (HBE).
fMLP was dissolved in dimethylsulfoxide (DMSO) as a 2
×1 0
-2 M stock solution, stored at -20°C and thawed
before use. The calcium ionophore A23187 and PMA
were both dissolved in DMSO as stock solutions of 1
mg/ml (1.91 mM and 1.62 mM respectively), stored at
-20°C and thawed before use. Working solutions of
fMLP, anti-IgE, A23187 and PMA were freshly prepared
in HBE supplemented with 5 mM CaCl2 and 2 mM
MgCl2 (HBC buffer). All reagents were pure and quality
checked; whenever necessary disposable plastic ware and
sterile apyrogenic solutions were used.
Subjects and sampling
A total of 70 blood donors volunteers (47% male, 53%
female) were enrolled in this study. Recruitment was
randomized and encompassed an age range from 24 to
65 yrs (mean 44.61 ± 4.57 SD) in order to have a wide
experimental population and to prevent age influence
on cell releasability [29]. All the subjects recruited in
the study were non allergic and non atopic, they did not
suffer of any immunological disorder and had never
reported any previous history or genetic diathesis of
chronic allergy; moreover, none underwent neither drug
therapy nor anti-histamine therapy during the 48 hrs
before the peripheral venous blood withdrawal. All par-
ticipants completed and signed a specific consenting
form for taking the samples and for data processing.
Cell recovery and preparation
Basophils were collected as leukocyte-enriched buffy
coats from venous K2-EDTA anticoagulated peripheral
blood from four screened healthy donors in each
Chirumbolo et al. Clinical and Molecular Allergy 2010, 8:13
http://www.clinicalmolecularallergy.com/content/8/1/13
Page 2 of 12experiment performed, according to previously
described methods [28]. Buffy coats were pooled and
suspended in HBE buffer. To count basophils and eval-
uate yields, an aliquot of about 1 ml of the cell culture
was transferred to a Bayer ADVIA 2120 automated
hematocytometer [30]. The volume of working cell
suspensions was adjusted with HBE buffer in order to
get a basophil count of 90-150 basophils/μl. Compared
with hemocytometer counts of starting whole blood
(30-50 basophils/μl), an average enrichment of about
1.5-3.0 times (mean = 2.4) was currently obtained. Try-
pan blue exclusion test revealed that 98.7% ± 7.4 SD
leukocytes were viable. Aliquots (100 μl) of cell sam-
ples were incubated at 37°C for 10 minutes with an
equal volume of HBE in the absence or in the presence
of quercetin or wortmannin at the indicated final
doses. Activation was performed by adding 50 μlo f
treated cells to 50 μl of HBC buffer containing
200 nM fMLP or 8 μg/ml of goat anti-human IgE or
1.0 μM A23187 or 100 nM PMA, according to the
different protocols. Resting assays were performed by
incubating cells in HBC buffer without agonists. Incu-
bation was carried out at 37°C for 30 minutes and
blocked by adding 100 μl of ice-cold HBE supplemen-
ted with 2.8 mM sodium-EDTA (Na3-EDTA). Then
the samples were put on ice and stained with mono-
clonal antibodies (20 minutes at +4°C), according to
previously published methods [28]. Afterwards, red
blood cells underwent lysis with an ammonium-buf-
fered solution (155 mM NH4Cl, 10 mM Na2HCO3,
0.10 mM Na3EDTA, pH = 7.2) for 4 minutes at +4°C;
then samples were centrifuged at 700 g and pellets
recovered and re-suspended in a PBS-buffered saline
solution (pH 7.4) for flow cytometry reading.
Histamine release
Cells treated with different concentration of quercetin
and activated with the indicated agonists, were pelleted
at 6000 rpm for 5 minutes and surnatants collected for
a competitive histamine ELISA test. 25 μl of each sam-
ple was treated with buffers and an acylation reagent,
incubated for 1 hour at r.t. and diluted with 200 μlo f
distilled water. Aliquots of 20 μl of these acylated sam-
ples were incubated overnight with 100 μlo fa n t i -
serum, washed 3 times, incubated for 1 hr at r.t. with
a horseradish peroxidase-conjugate, washed 3 times
with washing buffer, incubated for 30 min at r.t. with
the colorimetric substrate tetramethylbenzidine and
reaction stopped. The absorbance of the solution in
each wells was read within 10 minutes at 450 nm with
a reference wavelength of 620 nm. Histamine was cal-
culated as ng/ml of the released amine against the cor-
responding standard concentrations in the calibration
curve.
Flow cytometry and data processing
Basophil membrane markers were evaluated by flow
cytometry using a five-color fluorochrome panel includ-
ing CD45-APCCy7, CD123-PECy5 and HLA-DR-PECy7
as phenotyping markers and CD63-FITC and CD203c-
PE as activation ones [28]. Flow analysis was performed
using a 488 nm-633 nm two-laser BD FACScanto flow
cytometer: the instrument had a 10,000 events/sec cap-
ability, six-color detection and 0.1% sample carryover.
Analysis were performed with a mean flow rate of 300-
500 events/sec, setting an excess limit of 50,000 events
to record in the basophil gate in order to analyze the
whole buffered suspension volume and having a proper
estimation of cell recovery and reproducibility. Compen-
sation followed cytometer manufacturer’s instruction
according an off-line procedure by applying automated
electronics algorithms and preset templates, by using
biparametric logarithmic dot plots, gate-specific tubes
and single-tube data analysis, and optimizing FSC
threshold and fluorochrome voltage as set up para-
meters. Mean of fluorescence intensity (MFI) was calcu-
lated automatically by the cytometer software.
Percentage of activated cells was calculated by the soft-
ware considering the CD63 expressing cells (CD63-
FITC
positive cells) counted to the right of a threshold
that was established including the main peak of fluores-
cence of a sample of resting cells. In order to reduce
standard deviation due to positive fluorescent cells
respect to negative or dimly ones, a logarithmic scale
and a coefficient of variation to measure variability
dispersion were used.
Statistics
Data were analyzed using the software SPSS, version 11
for Windows, Chicago, IL. Dose response curves were
obtained by plotting the triplicate data and their mean
values and S.E.M. for each experiment using the Sigma
plot 10 software. Kolmogorov-Smirnov and Shapiro-
Wilk goodness-of-fit tests were performed to determine
whether the sample population followed a Gaussian dis-
tribution. Differences between quercetin-treated and
non-treated cells were analyzed by using a one-way ana-
lysis of variance (ANOVA) followed by Fisher LSD test.
Av a l u eo fp < 0.05 was considered statistically signifi-
cant. IC50 was calculated for each curve of percentage of
effect/control by a linear regression calculation accord-
ing to the four parameter logistic model (4PL), also
called the Hill-Slope model.
Results
Basophils stimulated with anti-IgE or fMLP
Figure 1 shows the dose response of the flavonoid quer-
cetin on the expression of human basophil activation
markers CD63 and CD203c following stimulation with
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D,E,F). In basophils stimulated with anti-human IgE,
quercetin was able to inhibit in a dose-dependent fash-
ion both the tetraspan (Figure 1, panels A,B) and the
ectoenzyme up-regulation (Figure 1 panel C); quercetin
IC50 able to inhibit CD63 expression was about 0.132
μM (values were 0.119 μM and 0.136 μM for CD63-MFI
and for CD63
expr%, respectively) while IC50 was about
6-fold higher (0.775 μM) for CD203c. In basophils acti-
vated with formylated peptides the flavonoid inhibited
the activation markers at concentrations higher than
1.0 μM while it enhanced the same response at the
doses of 0.033 μM and 0.33 μM (Figure 1 panels D,E),
showing a typical bimodal hormetic pattern. Priming
phenomenon (from 138.5% to 152.4% of untreated cells)
was observed with the lowest quercetin concentration
used in the assay, namely 0.033 μM and appeared more
pronounced for CD63 expression than for CD203c one
(Figure 1 panel F).
Basophils stimulated with the calcium ionophore A23187
or with PMA
Quercetin showed also a marked ability to decrease in a
dose-dependent fashion the expression of CD63 in
basophils activated with the calcium ionophore A23187
(Figure 2, panels A,B). Values of IC50 for CD63-MFI
and for CD63
expr% were respectively 0.573 μMa n d
0.824 μM. The expression of CD203c was much more
resistant to the inhibition by quercetin (Figure 2, panel
C): this evidence suggests some dissociation concerning
the action of quercetin on calcium signaling of the two
activation markers.
When basophils, following pre-incubation with differ-
ent concentrations of quercetin, were stimulated with
the PKC activator PMA (Figure 2, panels D,E,F), the fla-
vonoid did not show any significant inhibitory effect,
except for the highest concentration used in the experi-
ments (33 μM). The effect of quercetin showed a speci-
ficity for the activation markers, as other molecules used
to phenotype basophils, such as CD123, which recog-
nizes the alpha subunit of the constitutive basophil IL-3
receptor, was not affected by any of the quercetin con-
centrations used in any of the activation model consid-
ered in the study (Figure 3).
Basophil releasability by the histamine ELISA test
Basophils treated with increasing doses of pure aglycone-
quercetin were triggered with the different agonists used
Figure 1 Dose response of quercetin on membrane markers expression by anti-IgE (A,B,C) and fMLP (D,E,F) activated basophils.C e l l s
were pre-treated for 10 min at 37°C with increasing doses of quercetin, then stimulated for further 30 min at 37°C with 4 μg/ml anti-IgE or 100
nM fMLP, then evaluated as CD63 MFI (A, D), as the percentage of cells expressing CD63 marker (B, E) and as CD203c MFI (C, F).Values are mean
± S.E.M. of triplicate assays. Figure is representative of one triplicate experiment of 4 performed.
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incubation at 37°C was assayed with a competitive ELISA
kit. Results are described in Figure 4: basophil releasability
(degranulation) exhibited the same dose response behavior
performed by the activation marker, particularly for CD63,
namely a strong dose-response inhibition following anti-
IgE activation (Figure 4, panel A), a bimodal pattern in the
bacterial peptide activation protocol (Figure 4, panel B), a
dose-response inhibition in the calcium ionophore stimu-
latory assay (Figure 4, panel C), and no inhibitory effect in
the PMA activation pattern (Figure 4, panel C). The same
cell population was investigated in the same experimental
setting about CD63 and CD203c and CD123 membrane
expression by flow cytometry: the behavior of these mar-
kers under the effect of quercetin was similar, in the var-
ious experimental conditions, to the behavior of histamine
(data non shown).
Wortmannin dose-response
Taking into account the two main activation proto-
cols, namely the IgE-mediated and the fMLP
mediated stimulation, basophils were treated with
the specific PI3K inhibitor wortmannin in order to
focus on a possible pathway involved in the bimodal
behavior observed with the different agonists: the
overall impression is that wortmannin behaved simi-
larly to quercetin in our tested models. Figure 5
shows the dose response of wortmannin on baso-
phils triggered with 4 μg/ml anti-IgE: it showed a
pronounced inhibitory activity, with an IC50 of 2.17
×1 0
-9 Ma n d1 . 9 9×1 0
-9 Mf o rC D 6 3( F i g u r e5
panels A,B respectively) and 2.63 × 10
-9 Mf o r
CD203c (Figure 5, panel C). When basophils were
activated with a formylated peptide, wortmannin
showed a strong inhibitory action in the micromolar
range and an increasing expression of CD63-MFI
and of CD203c in the nanomolar range (Figure 6
panels A,B,C), surprisingly performing a biphasic or
hormetic behavior as like as quercetin. Wortmannin,
too, did not affect significantly the expression of a
non activable marker such as CD123 (Figures 5 and
6, panel D).
Figure 2 Dose response of quercetin on membrane markers expression by calcium ionophore (A,B,C) and PMA (D,E,F) activated
basophils. Cells were pre-treated for 10 min at 37°C with increasing doses of quercetin, then stimulated for further 30 min at 37°C with 0.5 μM
calcium ionophore A23187 or 50 nM PMA, then evaluated as CD63 MFI (A, D), as the percentage of cells expressing CD63 marker (B, E) and as
CD203c MFI (C, F). Values are mean ± S.E.M. of triplicate assays. Figure is representative of one triplicate experiment of 4 performed.
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The results here presented confirm the inhibitory action
of relatively high concentrations of quercetin on human
basophils function previously reported by others
[19,31,32] and by us [20] and assess putative mechan-
isms of the observed effects at the nanomolar dose
range. Quercetin has many targets among intracellular
kinases involved in many steps of receptor downstream
signaling, leading to various effector functions, such as
the degranulatory event [26] but its strong inhibitory
action has usually been shown at the high micromolar
concentration range, where biphasic effects were not
reported. At highest micromolar doses, quercetin
actually inhibits a variety of intracellular kinases but at a
concentration range from 10
-7 Mt o1 0
-8 Mt h ea c t i o n
of quercetin might depend on more specific and sensi-
tive steps of the activatory pathway used by the cell,
probably on the receptor signaling complex. The impor-
tance of distinguishing the effects on the basis of
in vitro acting dose range is also related to the evidence
reported elsewhere by in vivo studies that the plasma
concentration of quercetin in healthy volunteers follow-
ing food supplementation ranged from 0.43 μMt o
1.5 μM [33-35]. Here below, we would discuss the abil-
ity of quercetin to act as a modulatory compound in a
sub-micromolar/nanomolar concentration range, taking
Figure 3 Dose response of quercetin on membrane markers expression, evaluated as CD123-PECy5 MFI, in basophils activated with 4
μg/ml anti-IgE (A), 100 nM fMLP (B), 0.5 μM calcium ionophore A23187 (C) or 50 nM PMA (D). Cells were pre-treated for 10 min at 37°C
with increasing doses of quercetin, then stimulated for further 30 min at 37°C with the indicated agonists. Values are mean ± S.E.M. of triplicate
assays. Figure is representative of one triplicate experiment of 4 performed for each series of different stimuli.
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hypotheses.
Q1) Effects of quercetin in the FcεRI-anti-IgE activa-
tion model. Previously published reports have shown
that quercetin is able to inhibit PI3K by binding to the
catalytic pocket of the enzyme: as for instance,
LY294002, a synthetic inhibitor of PI3K, has actually a
chemical kinship with the flavonoid quercetin [36].
The IC50 for quercetin as an inhibitor of PI3K from
human blood platelets is around 1.8-20 μM[ 3 7 ] ,
which corresponds to the inhibitory range observed in
the results here reported on basophils. Taking into
account the downstream signaling pathway of FcεRI-
anti-IgE complex, a suggestion would come that the
inhibition of PI3K leads to the loss of phosphorylation
of downstream kinases such as Bruton’s tyrosine kinase
( B T K )[ 3 8 ]w h i c hi nt u r ni sa b l et op h o s p h o r y l a t e
PLCg, thus leading to the production of inositol-1,4,5-
triphosphate (IP3) and to diacylglycerol (DAG) from
the precursor phosphatidylinosytol-4,5-biphosphate
Figure 4 Quercetin dose-response evaluated by assaying histamine release with an ELISA commercial kit. Histamine is expressed as ng/
ml of the vasoactive amine. Basophils were pre-treated 10 min at 37°C with increasing doses of quercetin and subsequently stimulated for
further 30 min at 37°C with 4 μg/ml anti-IgE (A), 100 nM fMLP (B), 0.5 μM calcium ionophore A23187 (C) or 50 nM PMA (D). Values are mean ±
S.E.M. of 3 different triplicate assays. Negative control: cells which did not undergo any treatment with quercetin and the agonist (resting cells);
positive control: cells treated with the agonist but not treated with quercetin. One way global ANOVA for activated samples series: A) p <
0.0001; B) p < 0.001; C) p = 0.034; D) p = 0.65. Post-hoc (LSD) analysis of each dose as compared to positive control is indicated above the
respective bar chart as: (**) p < 0.01; (***) p < 0.001.
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to the membrane, IP3 diffuses to the cytosol and binds
to and activates the InsP3 receptor on the membrane
of the endoplasmic reticulum, opening a calcium chan-
nel, resulting in the release of Ca
2+ into the cytoplasm.
DAG is able to activate PKC, which in turn activates
membrane markers up-regulation and histamine
release [39]. Warner et al. observed that the amount of
histamine release associated with activation of baso-
phils through IgE receptor aggregation, among differ-
ent preparations of basophils, was correlated with an
increase in membrane bound PKC-like activity [40].
These results also suggested that PKC activation may
h a v ear o l ei nI g E - m e d i a t e dh i s t a m i n er e l e a s ei n
human basophils and that quercetin might inhibit
basophil function by blocking DAG precursor for PKC
in the upstream signaling pathways. The inhibition of
PI3K by quercetin would also prevent the formation of
phosphatidylinositol 3,4,5-triphosphate (PtdIns3,4,5-P3)
which activates extracellular calcium influx by mem-
brane Ca
++ channels [41].
Q2) Effects of quercetin in the FPR-fMLP activation
model. Figure 7 depicts a speculative suggestion con-
cerning the priming phenomenon observed on the
fMLP-triggered basophil function. Since in our assay
system the effects of quercetin were superimposable to
those of wortmannin, a potent PI3K inhibitor [42,36],
our results indirectly suggest a role for PI3K in the dual
effects performed by the flavonoid. G-protein coupled
receptors, such as the fMLP receptor, activate the PI3Kg
isoform through interactions with Gbg of the PI3K p101
and p110g subunits [43]. Increasing evidence suggests
Figure 5 Wortmannin dose-response in anti-IgE activated basophils, by assaying CD63 MFI (A), CD63
expr % (B) CD203c MFI (C) and
CD123 MFI (D). Basophils were pre-treated 10 min at 37°C with increasing doses of wortmannin and subsequently stimulated for further 30
min at 37°C with 4 μg/ml anti-IgE. Values are mean ± S.E.M. of triplicate assays of 2 separate experiments performed. Negative and positive
controls as in legend of Figure 4. One way global ANOVA for activated samples: A) p < 0.0001; B) p < 0.0001; C) p < 0.001; D) p = 0.76. Post-hoc
(LSD) analysis of each dose as compared to positive control is indicated above the respective bar chart as: (*) p < 0.05; (***) p < 0.001.
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regulator of G-protein coupled receptor dependent sig-
nal transduction [43]: Gbg is able to activate a G-
coupled receptor kinase (GRK) which desentitizes the
receptor. Interactions of quercetin with this Gbg-p101/
p110g might exert an action leading to these possible
results: a) the inability of Gbg sequestered by p101/
p110g complex to activate G-coupled receptors kinases
(GRKs) and to desensitize the receptor, leading to a
priming mechanism for example by inducing a sustained
activation of downstream protein kinases involved in the
degranulatory event, such as p38-MAPK [44]; b) the
long-lasting activation of Gbg-associated PLCb due to a
defect in the Gbg/PI3K dissociation, leading to an
increase in signaling mediators able to trigger the
degranulation event (by IP3-calcium signaling or by the
activation of DAG-PKC pathway), so resulting in a
priming effect.
Q3) Effect of quercetin on protein kinase C (PKC)
activation pathway. In our assay system the flavonol
proved insensitive to target protein kinase C (PKC), as
resulted from the use of PMA as basophil stimulant,
thus confirming previous reports [19]: quercetin was
unable to inhibit CD63 and CD203c membrane up-reg-
ulation in basophils stimulated with phorbol esters and
no dissociation between the two markers investigated
was actually observed by using PMA [45]. So, the PKC
pathway triggered by PMA, and presumably by other
physiologic stimulants, is a quercetin-insensitive route
to basophil activation.
Figure 6 Wortmannin dose-response in fMLP-activated basophils, by assaying CD63 MFI (A), CD63
expr % (B) CD203c MFI (C) and
CD123 MFI (D). Basophils were pre-treated 10 min at 37°C with increasing doses of wortmannin and subsequently stimulated for further 30
min at 37°C with 100 nM fMLP. Values are mean ± S.E.M. of triplicate assays of 2 separate experiments performed. Negative and positive controls
as in legend of Figure 4. One way global ANOVA for activated samples: A) p < 0.001; B) p < 0.001; C) p < 0.001; D) p = 0.69. Post-hoc (LSD)
analysis of each dose as compared to quercetin untreated cells is indicated above the respective data point as: (*) p < 0.05; (**) p < 0.01; (***) p
< 0.001.
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calcium ionophore A23187. In response to calcium
ionophore A23187 the expression of both the activation
markers CD63 and CD203c was markedly up-regulated,
but quercetin exerted a significant inhibitory action,
even at nanomolar doses, only on CD63, so dissecting
the response of the two activation markers to the iono-
phore. Previous evidence has reported that CD203c and
CD63 upregulation in response to calcium signal by
A23187 showed different kinetics [28], an evidence that
probably suggests different pathways of calcium involve-
ment in the expression of the two markers [46].
Our results indicate that the calcium-mediated signaling
is essential both for the LAMP-1 CD63 and for the
ENPP-3 CD203c upregulation, as A23187-mediated cal-
cium influx stimulate both the expression of basophil
activation markers and histamine release (see Figure 7),
but on the same time they suggest also that the trans-
duction pathway diverges in two distal branches, one of
which (LAMP-1) is sensitive to quercetin and is related
to the degranulatory event [47], the other is much more
resistant to this inhibition. It is well known that A23187
promotes the activation of Ca++/calmodulin pathway
[48], which is inhibited by quercetin [49]. Calmodulin
constitutes an obligate link in signal transduction path-
ways leading to human leukocyte histamine release if
the trigger is a calcium ionophore but not when
responses are induced by anti-IgE, fMLP or PMA [48].
Figure 7 Cartoon describing the possible pathways of inhibition or of priming/activation by quercetin (Q) in the activation models
explored in the study. Putative sites sensitive to quercetin are indicated close to the target proteins PI3Ks or calmodulin: for PKC, Q is included
in a dashed area, indicating no effect of the flavonoid on the kinase. Membrane markers are indicated by squares (CD63) or triangles (CD203c).
Arrows indicate links between different activation pathways while dashed arrows indicate precursors or metabolites incoming to the interior of
the cell from membrane and/or from the outside. For further explanation and comments see the text. BTK: Bruton’s tyrosine kinase; DAG:
diacylglycerol; GAB-2: Grb-associated binding protein-2, an adaptor protein serving as principal activator of PI3K; GRK: G-coupled receptor kinase;
IP3: inositol-1,4,5-triphosphate; PLC: phospholypase C; PtdIns 3,4-P2: phosphatidylinositol 3,4-biphosphate; PtdIns 4,5-P2: phosphatidylinositol 4,5-
biphosphate; PtdIns 3,4,5-P3: phosphatidylinositol 3,4,5-triphosphate; Syk, Lyn: signaling tyrosine kinases linked to IgE-high affinity receptor; other
abbreviations as in the text.
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Page 10 of 12Quercetin ability to target calmodulin drives to the sug-
gestion that those events inhibited by the flavonoid, i.e.
the histamine release and CD63 membrane up-regula-
tion, were presumably related to a Ca++/calmodulin
dependent pathway in basophils activated with A23187,
while the expression of CD203c, which was not signifi-
cantly affected by the flavonoid even at its highest dose,
might be a calmodulin-independent event. This marker
is probably translocated to the membrane by other cal-
cium dependent vesicular-transport mechanisms [50].
These hypotheses and models need for further investi-
gation on a molecular level such as a direct demonstra-
tion of the kinases isolated from or detected in the
purified basophils and/or by using isoform-selective
inhibitors of PI3K and to assay calmodulin involvement
in the A23187 activation pathway inhibited by quercetin.
What is really interesting is that the observed modula-
tory biphasic (hormetic) mechanism can be related to
the inhibition of PI3K by quercetin and that the effica-
cious doses are within the nanomolar plasma concentra-
tions reported in several pharmacokinetic and
bioavailability studies about this flavonoid [51-53]. At
these concentrations is commendable that quercetin
exerts a fine regulatory action depending on the fine
balancing of signaling proteins ruled by PI3Ks. The
PI3Ks seem to be strategic both for the activation of
downstream protein kinases and for receptor-associate
phospholypases C activation thus leading to calcium ele-
vation in the cytoplasm and to PKC-mediated degranu-
lation, two conditions which basophil needs for up-
loading its markers of activation on the membrane and
for histamine release. This might be a first step by
which quercetin is able to exert its action at sub-micro-
molar-nanomolar concentration range, while at the
highest doses its action might involve also other recep-
tor and PI3K-downstream kinases such as Akt/PKB,
MEK, p38-MAPK, etc. [26].
Allergy is a cause for concern, mainly due to its rising
prevalence inside the population and to the increasing
difficulty in treating chronic allergy. Quercetin might be
a good candidate with the potential to counter this
trend: an appropriate intake of this flavonol from food
and beverage or from supplemental administration
could be expected to improve allergy, to help anti-
inflammatory and anti-oxidative responses by the organ-
ism and to prevent the onset of allergic chronic diseases.
However our results introduce a caveat: although baso-
phils play an important role in mediating allergic
response and quercetin has proved to have an inhibitory
action on basophils following stimulation with anti-IgE
and calcium ionophore A23187, the existing bimodal
effects of the flavonol and the complex nature of hyper-
sensitivity reactions would require researchers be more
cautious before considering quercetin in the practical
use of the therapy and prevention of allergy. To achieve
this goal, further research insights about cell signaling
and about quercetin intracellular targets and studies in
animal models are required.
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